Gemcitabine alone or plus cisplatin for biliary tract cancer?
Author:
- 29 September 2010
- journal article
- Published by Springer Nature in Nature Reviews Clinical Oncology
- Vol. 7 (10) , 554-555
Abstract
No abstract availableThis publication has 10 references indexed in Scilit:
- Molecular markers and biological targeted therapies in metastatic colorectal cancer: expert opinion and recommendations derived from the 11th ESMO/World Congress on Gastrointestinal Cancer, Barcelona, 2009Annals of Oncology, 2010
- Cisplatin plus Gemcitabine versus Gemcitabine for Biliary Tract CancerNew England Journal of Medicine, 2010
- A randomized study of gemcitabine/cisplatin versus single-agent gemcitabine in patients with biliary tract cancerJournal of Clinical Oncology, 2009
- Chemotherapy in advanced biliary tract carcinoma: a pooled analysis of clinical trialsBritish Journal of Cancer, 2007
- Identification of Novel Cellular Targets in Biliary Tract Cancers Using Global Gene Expression TechnologyThe American Journal of Pathology, 2003
- Mutations of the BRAF gene in cholangiocarcinoma but not in hepatocellular carcinomaGut, 2003
- Phase II trial of cisplatin and gemcitabine in advanced squamous-cell carcinoma of the head and neckAnnals of Oncology, 1998
- Cisplatin-gemcitabine combination in advanced non-small-cell lung cancer: a phase II study.Journal of Clinical Oncology, 1997
- Chemotherapy improves survival and quality of life in advanced pancreatic and biliary cancerAnnals of Oncology, 1996
- Synergistic interaction between cisplatin and gemcitabine in vitro.1996